The field of targeted therapeutics has benefitted immeasurably from the development of high-
affinity antibodies. These important ligands have facilitated the development of effective …

It has been over four decades since the development of monoclonal antibodies (mAbs)
using a hybridoma cell line was first reported. Since then more than thirty therapeutic …

Monoclonal antibodies (mAbs) are well established in the clinic due to their specificity and
affinity to a diverse array of biochemical targets. More recently, mAbs are being exploited as …

Systemic chemotherapy, the current standard of care for the treatment of cancer, is rarely
curative and is often accompanied by debilitating side effects. Targeted drug delivery stands …

Antibody–drug conjugates (ADCs) combine the specificity of antibodies with the potency of
small molecules to create targeted drugs. Despite the simplicity of this concept, generation of …

Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine
the specificity of therapeutic antibodies with the pharmacological potency of chemical …

Introduction In the field of bioconjugates, the focus on antibody–drug conjugates (ADCs)
with novel payloads beyond the traditional categories of potent cytotoxic agents is …

Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy,
combining the antibody's exquisite specificity for the target antigen-expressing cancer cell …